Observational studyFEBS open bio2021
Long non-coding RNA SOX21-AS1 enhances the stemness of breast cancer cells via the Hippo pathway.
Observational study in FEBS open bio, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 18 citations in OpenAlex.
- LncRNA SOX21-AS1 Promotes the Progression of Pancreatic Cancer by Sponging miR-9-3p and Upregulating YOD1.The Kaohsiung journal of medical sciences · 2025Article
- A cutting-edge investigation of the multifaceted role of SOX family genes in cancer pathogenesis through the modulation of various signaling pathways.Functional & integrative genomics · 2025Review
- Interaction of noncoding RNAs with hippo signaling pathway in cancer cells and cancer stem cells.Non-coding RNA research · 2024Review
- Review
- RNA-seq analysis identifies transcriptomic profiles associated with anal cancer recurrence among people living with HIV.Annals of medicine · 2023Article
- Long non-coding RNAs in breast cancer stem cells.Medical oncology (Northwood, London, England) · 2023Review
- SRY-box transcription factor 21 antisense divergent transcript 1: Regulatory roles and clinical significance in neoplastic conditions and Alzheimer's Disease.Journal of Cancer · 2023Review
- Review
- Review
- Comprehensive analysis of cuproptosis-related lncRNAs model in tumor immune microenvironment and prognostic value of cervical cancer.Frontiers in pharmacology · 2022Article
- Coding roles of long non-coding RNAs in breast cancer: Emerging molecular diagnostic biomarkers and potential therapeutic targets with special reference to chemotherapy resistance.Frontiers in genetics · 2022Review
- Epigenetic Regulation of Breast Cancer Stem Cells Contributing to Carcinogenesis and Therapeutic Implications.International journal of molecular sciences · 2021Review
- Signaling pathways governing breast cancer stem cells behavior.Stem cell research & therapy · 2021Review
- LncRNAs and microRNAs as Essential Regulators of Stemness in Breast Cancer Stem Cells.Biomolecules · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer stem cells (BCSCs) have high tumorigenicity and invasiveness, which contributes to recurrence and metastasis. The long non-coding RNA SOX21-AS1 has been previously reported to modulate the properties of breast cancer stem cells via targeting SOX2, although the underlying molecular mechanisms remain unclear. To investigate this issue, we first confirmed that the expression level of SOX21-AS1 is increased in breast cancer tissues and cell lines (MCF-7, MDA-MB-231, CSC-MCF-7, CSC-MDA-MB-231), especially in BCSCs. We demonstrated that SOX21-AS1 promotes the stemness of CSC-MCF-7 cells through western blot detection of stemness-related proteins, as well as side population and sphere formation assays. Overexpression of SOX21-AS1 enhanced the proliferation, migration and invasion of CSC-MCF-7 cells. We also observed that SOX21-AS1 inhibited the Hippo pathway. SOX21-AS1 enhanced the stemness, migration and invasion of CSC-MCF-7 cells by increasing the nuclear localization of YAP and decreasing the level of pYAP. Overall, we conclude that SOX21-AS1 may promote the stemness viability, proliferation, migration and invasion of BCSCs by inhibiting the Hippo pathway. Our findings provide insights into potential biomarkers and prognostic measures for the treatment of breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.